| 08:08a | Citigroup Adjusts DexCom's Price Target to $525 From $630, Reiterates Buy Rating | MT |
| 05/11 | TRANSCRIPT : DexCom, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2.. | CI |
| 05/10 | Dexcom Announces Upcoming Conference Presentations | BU |
| 04/29 | Raymond James Adjusts DexCom's Price Target to $486 From $538, Keeps Outperform Rating | MT |
| 04/29 | Morgan Stanley Adjusts Price Target for DexCom to $492 From $514, Maintains Equalweigh.. | MT |
| 04/29 | SVB Leerink Adjusts DexCom's Price Target to $500 From $565, Keeps Outperform Rating | MT |
| 04/29 | Piper Sandler Adjusts DexCom's Price Target to $480 From $725, Reiterates Overweight Ra.. | MT |
| 04/28 | DEXCOM : Reports First Quarter 2022 Financial Results - Form 8-K | PU |
| 04/28 | TRANSCRIPT : DexCom, Inc., Q1 2022 Earnings Call, Apr 28, 2022 | CI |
| 04/28 | DEXCOM UPDATES FIRST QUARTER 2022 CO : 30 p.m. Eastern Time | BU |
| 04/28 | DexCom's Q1 Earnings Down as Revenue Decreases | MT |
| 04/28 | DEXCOM : Q1 Earnings Snapshot | AQ |
| 04/28 | Earnings Flash (DXCM) DEXCOM Reports Q1 Revenue $628.8M, vs. Street Est of $624M | MT |
| 04/28 | Earnings Flash (DXCM) DEXCOM Reports Q1 EPS $0.32, vs. Street Est of $0.52 | MT |
| 04/28 | Dexcom, Inc. Reiterates Earnings Guidance for the Full Year 2022 | CI |
| 04/28 | Dexcom Reports First Quarter 2022 Financial Results | BU |
| 04/28 | DexCom, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
| 04/28 | EARNINGS REACTION HISTORY : DEXCOM INC, 87.5% Follow-Through Indicator, 8.6% Sensitive | MT |
| 04/26 | DexCom Showcases Expanded CGM Portfolio at International ATTD Conference, Offering More.. | BU |
| 04/26 | DexCom, Inc. Showcases Expanded CGM Portfolio at International ATTD Conference | CI |
| 04/13 | INSIDER SELL : Dexcom | MT |
| 04/07 | Dexcom Publishes Annual Sustainability Report | BU |
| 04/07 | DEXCOM : G6 Continous Glucose Monitoring System Now Available Through Tricare Pharmacy Ben.. | PU |
| 04/01 | Equites Fall Midday as Parts of Yield Curve Turning Negative Undermine Sentiment | MT |
| 04/01 | DexCom to Introduce Dexcom One in UK During May | MT |
| 04/01 | Dexcom Announces Dexcom ONE, the Newest Real-Time Continuous Glucose Monitoring System,.. | BU |
| 04/01 | Dexcom Announces Dexcom ONE, the Newest Real-Time Continuous Glucose Monitoring System,.. | CI |
| 03/31 | DEXCOM SCHEDULES FIRST QUARTER 2022 : 30 p.m. Eastern Time | BU |
| 03/31 | CAPITALGAINSREPORT : Healthcare Sector Offers Consistent Upside To Investors | AQ |
| 03/25 | US Stocks Post Gains For Second Straight Week as Treasury Yields Surge Friday | MT |
| 03/25 | Equities Under Pressure Midday as Yields Surge Amid Expectations for Aggressive Fed Rat.. | MT |
| 03/25 | DexCom Plans 4-to-1 Stock Split | MT |
| 03/25 | Dexcom Announces Four-for-One Forward Stock Split | BU |
| 03/24 | INSIDER SELL : Dexcom | MT |
| 03/14 | SECTOR UPDATE : Health Care Advancing to Begin New Week | MT |
| 03/14 | SECTOR UPDATE : Health Care | MT |
| 03/14 | DexCom Secures Europe's CE Mark for G7 Continuous Glucose Monitoring System | MT |
| 03/14 | Dexcom G7 Receives CE Mark – Next-Generation Continuous Glucose Monitoring System.. | BU |
| 03/07 | Ontario Announces Public Coverage for the Dexcom G6 Continuous Glucose Monitoring Syste.. | BU |
| 03/02 | BofA Securities Reinstates DexCom at Buy With $500 Price Target | MT |
| 03/01 | FDA Grants Breakthrough Device Designation for Dexcom Hospital CGM System | BU |
| 02/23 | TRANSCRIPT : DexCom, Inc. Presents at Citi’s 2022 Virtual Healthcare Conference, Feb-.. | CI |
| 02/16 | TRANSCRIPT : DexCom, Inc. Presents at 11th SVB Leerink Annual Global Healthcare Conference.. | CI |
| 02/16 | INSIDER SELL : Dexcom | MT |
| 02/14 | Dexcom Announces Upcoming Virtual Conference Presentations | BU |
| 02/11 | DEXCOM : Q4 Earnings Snapshot | AQ |
| 02/11 | SECTOR UPDATE : Health Care Stocks Tumble Friday Afternoon | MT |
| 02/11 | SECTOR UPDATE : Health Care Stocks Unable to Sustain Early Advance | MT |
| 02/11 | Morgan Stanley Cuts Price Target on DexCom to $514 From $570, Maintains Equalweight Rat.. | MT |
| 02/10 | TRANSCRIPT : DexCom, Inc., Q4 2021 Earnings Call, Feb 10, 2022 | CI |
| 02/10 | DexCom Reports Lower Q4 Adjusted Earnings, Higher Revenue; Reiterates 2022 Sales Guidan.. | MT |
| 02/10 | DEXCOM : Reports Fourth Quarter and Fiscal Year 2021 Financial Results - Form 8-K | PU |
| 02/10 | DexCom, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 | CI |
| 02/10 | Earnings Flash (DXCM) DEXCOM Posts Q4 Revenue $698.2M, vs. Street Est of $698.7M | MT |
| 02/10 | Dexcom Reports Fourth Quarter and Fiscal Year 2021 Financial Results | BU |
| 02/10 | Earnings Flash (DXCM) DEXCOM Posts Q4 Revenue $698.2M, vs. Street Est of $698.7M | MT |
| 02/10 | DexCom, Inc. Reiterates Earnings Guidance for the Fiscal Year 2022 | CI |
| 02/10 | DexCom, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021 | CI |
| 02/10 | EARNINGS REACTION HISTORY : DEXCOM INC, 77.8% Follow-Through Indicator, 8.8% Sensitive | MT |
| 02/04 | NORTH AMERICAN MORNING BRIEFING : Amazon.com, Snap -2- | DJ |
| 02/03 | Dexcom G6 Continuous Glucose Monitoring System Now Covered in Alberta for Children and .. | BU |
| 02/03 | BTIG Upgrades DexCom to Buy from Neutral, Sets $535 Price Target | MT |
| 01/31 | Oppenheimer Adjusts DexCom's Price Target to $580 From $630, Maintains Outperform Ratin.. | MT |
| 01/31 | Exclusive-U.S. diabetes deaths top 100,000 for second straight year, federal panel urge.. | RE |
| 01/28 | Health Care Stocks Still Advancing Ahead of Friday Close | MT |
| 01/28 | Health Care Stocks Posting Modest Gains | MT |
| 01/28 | Insulet Shares Rally on FDA Approval of Omnipod 5 | DJ |
| 01/28 | Insulet Gets FDA OK for Omnipod 5 Automated Insulin-Delivery System | DJ |
| 01/28 | Insulet Secures FDA Clearance for its Omnipod 5 Automated Insulin Delivery System | MT |
| 01/24 | DEXCOM SCHEDULES FOURTH QUARTER AND : 30 p.m. Eastern Time. | BU |
| 01/21 | INSIDER SELL : Dexcom | MT |
| 01/19 | DexCom Shares Rise After Wells Fargo Upgrade | MT |
| 01/19 | Raymond James Adjusts DexCom's Price Target to $538 from $618, Keeps Outperform Rating | MT |
| 01/19 | Wells Fargo Upgrades DexCom to Overweight From Equalweight; Price Target is $575 | MT |
| 01/11 | UBS Adjusts DexCom Price Target to $640 From $660, Maintains Buy Rating | MT |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
